[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Nasdaq Futures Climb as Chip Stocks Rebound Ahead of First Fed Decision Under Warsh

June Nasdaq 100 E-Mini futures (NQM26) are up +0.54% this morning, signaling a rebound from yesterday’s selloff, while investors await the first Federal Reserve rate decision under Kevin Warsh.

Nasdaq 100 futures were buoyed by a rebound in chip stocks. Micron Technology (MU), Marvell Technology (MRVL), and KLA Corp. (KLAC) rose more than +2% in pre-market trading.

Fundamentals

See More
  • Market Capitalization, $K 25,378,432
  • Shares Outstanding, K 396,786
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,412 M
  • EBITDA $ -3,264 M
  • 60-Month Beta 1.05
  • Price/Sales 12.61
  • Price/Cash Flow N/A
  • Price/Book 3.31

Options Overview Details

View History
  • Implied Volatility 79.65% (-2.07%)
  • Historical Volatility 72.24%
  • IV Percentile 84%
  • IV Rank 51.97%
  • IV High 103.33% on 11/03/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 6) 5.29 (8.27%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 139,103
  • Volume Avg (30-Day) 48,137
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 740,517
  • Open Int (30-Day) 679,426
  • Expected Range 58.67 to 69.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.00
  • Number of Estimates 9
  • High Estimate $-1.32
  • Low Estimate $-2.35
  • Prior Year $-2.13
  • Growth Rate Est. (year over year) +6.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.90 +45.69%
on 06/02/26
67.74 -5.58%
on 06/18/26
+15.85 (+32.95%)
since 05/18/26
3-Month
43.68 +46.43%
on 05/01/26
67.74 -5.58%
on 06/18/26
+11.56 (+22.06%)
since 03/18/26
52-Week
22.28 +187.07%
on 11/21/25
67.74 -5.58%
on 06/18/26
+38.56 (+151.81%)
since 06/18/25

Most Recent Stories

More News
FDA panel backs first-of-its-kind flu vaccine using mRNA technology

A new kind of flu vaccine is moving a step closer to the U.S. market

MRNA : 63.96 (+3.50%)
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026

MRNA : 63.96 (+3.50%)
Moderna to Host Investor Event - Science Day

CAMBRIDGE, MA / ACCESS Newswire / June 17, 2026 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Science Day at 9:00am ET on Thursday, June 25, 2026.

MRNA : 63.96 (+3.50%)
Nasdaq Futures Climb as Chip Stocks Rebound Ahead of First Fed Decision Under Warsh

June Nasdaq 100 E-Mini futures (NQM26) are up +0.54% this morning, signaling a rebound from yesterday’s selloff, while investors await the first Federal Reserve rate decision under Kevin Warsh.

KLAC : 259.56 (+8.73%)
MU : 1,133.99 (+8.70%)
RMD : 188.63 (+1.26%)
CBOE : 249.10 (-2.19%)
BMW.D.DX : 60.060 (+0.64%)
STMN.Z.IX : 104.950 (-0.14%)
SPCX : 185.00 (-3.56%)
LZB : 39.66 (-1.44%)
INTC : 133.99 (+10.64%)
NOW : 95.04 (-0.46%)
TEAM : 82.72 (-1.98%)
MRNA : 63.96 (+3.50%)
Why Is Moderna (MRNA) Stock Soaring Today

Why Is Moderna (MRNA) Stock Soaring Today

MRNA : 63.96 (+3.50%)
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028

Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease Franchises

MRNA : 63.96 (+3.50%)
3 Stocks Under $50 That Fall Short

3 Stocks Under $50 That Fall Short

RELL : 18.60 (+6.59%)
WBD : 26.20 (-0.15%)
MRNA : 63.96 (+3.50%)
How to Play PBLS Stock After the Parabilis IPO

Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.

KLRA : 19.90 (+4.03%)
PBLS : 25.85 (-0.69%)
MRNA : 63.96 (+3.50%)
3 Unpopular Stocks We Steer Clear Of

3 Unpopular Stocks We Steer Clear Of

NOV : 18.66 (-3.32%)
RPD : 6.73 (-0.59%)
MRNA : 63.96 (+3.50%)
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]

MRNA : 63.96 (+3.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 74.57
2nd Resistance Point 71.15
1st Resistance Point 67.56
Last Price 63.96
1st Support Level 60.55
2nd Support Level 57.13
3rd Support Level 53.54

See More

52-Week High 67.74
Last Price 63.96
Fibonacci 61.8% 50.37
Fibonacci 50% 45.01
Fibonacci 38.2% 39.65
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.